| Dr Maria Lm Olberding, MD | |
|
421 E Merle Hibbs Blvd, Marshalltown, IA 50158-4443 | |
| (641) 752-0099 | |
| (641) 752-8736 |
| Full Name | Dr Maria Lm Olberding |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 34 Years |
| Location | 421 E Merle Hibbs Blvd, Marshalltown, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003807900 | NPI | - | NPPES |
| 0158527 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 28343 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kindred At Home | Urbandale, IA | Home health agency |
| Wesley Life Home Health | Johnston, IA | Home health agency |
| Iowa Home Care, L L C | West des moines, IA | Home health agency |
| Care Initiatives Hospice - West Des Moines | West des moines, IA | Hospice |
| Iowa River Hospice | Marshalltown, IA | Hospice |
| Unitypoint Health-marshalltown | Marshalltown, IA | Hospital |
| Mary Greeley Medical Center | Ames, IA | Hospital |
| Grandview Heights Inc | Marshalltown, IA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mcfarland Clinic Pc | 1254244239 | 320 |
News Archive
TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company's existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.
Genentech, Inc., a member of the Roche Group today announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors.
Women with schizophrenia are nearly twice as likely to experience pre-eclampsia, pre-term birth and other serious pregnancy and delivery complications as women without the condition, a landmark study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital has found.
Temple University Hospital (TUH) could be among the first U.S.-based hospitals to test a new device known as a multilayer stent in patients suffering from aortic aneurysm, a condition characterized by the formation of a potentially life-threatening bulge in the aorta.
› Verified 3 days ago
| Entity Name | Mcfarland Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639135643 PECOS PAC ID: 1254244239 Enrollment ID: O20031106000338 |
News Archive
TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company's existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.
Genentech, Inc., a member of the Roche Group today announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors.
Women with schizophrenia are nearly twice as likely to experience pre-eclampsia, pre-term birth and other serious pregnancy and delivery complications as women without the condition, a landmark study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital has found.
Temple University Hospital (TUH) could be among the first U.S.-based hospitals to test a new device known as a multilayer stent in patients suffering from aortic aneurysm, a condition characterized by the formation of a potentially life-threatening bulge in the aorta.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maria Lm Olberding, MD 1215 Duff Ave, Ames, IA 50010-5400 Ph: (515) 239-4400 | Dr Maria Lm Olberding, MD 421 E Merle Hibbs Blvd, Marshalltown, IA 50158-4443 Ph: (641) 752-0099 |
News Archive
TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company's existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.
Genentech, Inc., a member of the Roche Group today announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors.
Women with schizophrenia are nearly twice as likely to experience pre-eclampsia, pre-term birth and other serious pregnancy and delivery complications as women without the condition, a landmark study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital has found.
Temple University Hospital (TUH) could be among the first U.S.-based hospitals to test a new device known as a multilayer stent in patients suffering from aortic aneurysm, a condition characterized by the formation of a potentially life-threatening bulge in the aorta.
› Verified 3 days ago
Blaine Brian Westemeyer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 S 4th Ave, Marshalltown, IA 50158 Phone: 641-754-5145 | |
Timothy Wayne Swinton, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 412 E Church St, Marshalltown, IA 50158 Phone: 641-753-4021 Fax: 641-753-4025 | |
Dr. David L. Thomas, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 303 Nicholas Dr, Marshalltown, IA 50158 Phone: 641-752-0099 Fax: 641-752-8736 | |
Somaia Selim, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 312 East Main, Marshalltown, IA 50158 Phone: 641-753-8616 Fax: 641-844-2205 | |
Dr. Joseph E Hoagbin, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1301 Summit St, Marshalltown, IA 50158 Phone: 641-753-1501 | |
Korie Jordan Eischeid, ARNP Family Medicine Medicare: Medicare Enrolled Practice Location: 101 Iowa Ave W, Ste 102, Marshalltown, IA 50158 Phone: 641-753-4021 Fax: 515-644-6792 |